Physician profile
Timothy R Olsen
NPI 1235478843
$124,298.36
in general payments reported to CMS, 2019-2025
26 companies · $26K in 2025
The $26K reported for 2025 was more than what 93% of Neuroscience (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $22K · 2023: $30K · 2024: $26K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Food and Beverage: $4,320 · Travel and Lodging: $4,074 · Consulting Fee: $675 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,985.00 |
| Food and Beverage | $4,320.25 |
| Travel and Lodging | $4,073.60 |
| Consulting Fee | $675.00 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106,131.15 | 2021-2025 | |
| Pfizer INC. | $13,121.96 | 2023-2025 | |
| Allergan, INC. | $1,941.66 | 2021 | |
| Ucb, INC. | $811.76 | 2021-2025 | Briviact, Nayzilam |
| Lundbeck LLC | $395.96 | 2021-2024 | Vyepti |
| Amgen INC. | $292.87 | 2021-2023 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $235.71 | 2021 | |
| Upsher-Smith Laboratories LLC | $223.95 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $195.26 | 2021-2023 | Ajovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $172.99 | 2022 | |
| Lilly USA, LLC | $160.73 | 2021-2023 | Emgality, Reyvow |
| Supernus Pharmaceuticals, INC. | $145.60 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $120.01 | 2022-2023 | Trudhesa |
| Sk Life Science, INC. | $81.77 | 2021-2023 | |
| Neurelis, INC. | $54.54 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39.23 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $26.41 | 2022 | |
| Zogenix INC. | $24.15 | 2021 | |
| Biogen, INC. | $23.98 | 2023 | Tysabri, Vumerity |
| Eisai INC. | $21.76 | 2023 | |
| Livanova USA, INC. | $14.97 | 2022 | |
| Currax Pharmaceuticals LLC | $14.91 | 2021 | |
| Merz Pharmaceuticals, LLC | $14.60 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $14.11 | 2021 | |
| Greenwich Biosciences, INC. | $12.56 | 2021 | |
| Sumitomo Pharma America, INC. | $5.76 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.